Want to see IBIO full AI Analyst Report?
Top Page
Ibio
(NASDAQ:IBIO)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▲(4.90% Upside)
Action:Reiterated
Date:07/02/26
The score is held down primarily by very weak financial performance (minimal revenue, large losses, and ongoing free-cash-flow burn), which raises financing/dilution risk despite low leverage. Technicals are neutral-to-mixed with only modest near-term improvement and still-below longer-term trend levels. Positive corporate events (clinical trial start and encouraging preclinical data) provide upside catalysts but are not yet reflected in operating profitability.
Positive Factors
Clinical-stage transition
Advancing IBIO-600 into first-in-human Phase 1 moves the company from preclinical toward clinical validation, materially reducing technical risk for that asset. Clinical entry can unlock partner interest, milestone funding, and clearer development milestones that support multi-quarter strategic planning.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flows indicate the business cannot self-fund development; this creates an ongoing dependency on external capital. Over a multi-quarter horizon, cash burn elevates refinancing and execution risk, potentially forcing dilution or delays in advancing programs if funding gaps arise.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical-stage transition
Advancing IBIO-600 into first-in-human Phase 1 moves the company from preclinical toward clinical validation, materially reducing technical risk for that asset. Clinical entry can unlock partner interest, milestone funding, and clearer development milestones that support multi-quarter strategic planning.
Read all positive factors
Ibio (IBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$69.55M
Dividend YieldN/A
Average Volume (3M)962.52K
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue Growth-20.00%
EPS Growth75.26%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.58
Shares Outstanding49,678,562
10 Day Avg. Volume806,879
30 Day Avg. Volume962,517
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)20.03
P/FCF Ratio-0.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.67Price Target Upside296.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$100.00K
Ibio Business Overview & Revenue Model
Company Description
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Biopr...
How the Company Makes Money
iBio’s revenue model is primarily tied to biopharmaceutical R&D and monetization of its technology and product candidates. Potential and historical sources of cash generation can include: (1) out-licensing or partnering its drug candidates or unde...
Ibio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 300.00K | 400.00K | 225.00K | 0.00 | 1.88M | 2.37M |
| Gross Profit | -480.00K | 400.00K | 225.00K | 0.00 | -1.91M | 909.00K |
| EBITDA | -26.40M | -17.04M | -14.02M | -27.85M | -25.72M | -28.55M |
| Net Income | -27.61M | -18.38M | -24.91M | -65.01M | -50.39M | -23.21M |
Balance Sheet | ||||||
| Total Assets | 85.83M | 23.18M | 28.73M | 41.21M | 99.41M | 146.97M |
| Cash, Cash Equivalents and Short-Term Investments | 74.80M | 8.58M | 14.21M | 7.33M | 33.52M | 96.97M |
| Total Debt | 2.33M | 3.51M | 4.46M | 17.07M | 25.77M | 32.72M |
| Total Liabilities | 8.30M | 8.30M | 7.41M | 25.83M | 35.92M | 38.40M |
| Stockholders Equity | 77.54M | 14.88M | 21.32M | 15.38M | 63.48M | 108.58M |
Cash Flow | ||||||
| Free Cash Flow | -22.16M | -15.32M | -18.76M | -36.17M | -45.13M | -35.23M |
| Operating Cash Flow | -21.61M | -15.30M | -18.55M | -30.44M | -37.80M | -30.06M |
| Investing Cash Flow | -27.54M | 742.00K | 906.00K | 7.01M | -5.13M | -26.48M |
| Financing Cash Flow | 91.82M | 8.93M | 24.49M | 2.30M | -5.80M | 78.83M |
Ibio Technical Analysis
Neutral
1.43
Price Trends
1.61
Negative
1.76
Negative
1.83
Negative
Market Momentum
-0.05
Negative
47.92
Neutral
72.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Neutral. The current price of 1.43 is above the 20-day moving average (MA) of 1.42, below the 50-day MA of 1.61, and below the 200-day MA of 1.83, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 47.92 is Neutral, neither overbought nor oversold. The STOCH value of 72.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IBIO.
Ibio Risk Analysis
Ibio disclosed 59 risk factors in its most recent earnings report. Ibio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ibio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $11.16M | -1.41 | -67.85% | ― | ― | 63.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $6.35M | -1.41 | -102.06% | ― | -100.00% | 62.88% | |
46 Neutral | $69.55M | -2.43 | -53.86% | ― | -20.00% | 75.26% | |
44 Neutral | $185.42M | -0.14 | 359.80% | ― | ― | -3629.03% | |
40 Underperform | $4.26M | -0.11 | -767.07% | ― | ― | 22.10% |
* Healthcare Sector Average
IBIO
Ibio
1.40
0.80
135.29%
NERV
Minerva Neurosciences
4.35
2.55
141.00%
PULM
Pulmatrix
1.65
-3.66
-68.93%
CMMB
Chemomab Therapeutics
1.75
-2.17
-55.36%
ASBP
Aspire Biopharma Holdings
7.26
-377.10
-98.11%
FBLG
FibroBiologics, Inc.
0.87
-9.86
-91.91%
Ibio Corporate Events
Regulatory Filings and ComplianceShareholder Meetings
iBio Updates Governance Deadlines for 2026 Annual Meeting
Neutral
Jul 17, 2026
iBio, Inc. has scheduled its 2026 Annual Meeting of Stockholders for October 14, 2026, with a record date of September 1, 2026 for determining shareholders entitled to vote. The time and location of the meeting will be provided in the company̵...
Business Operations and StrategyProduct-Related Announcements
iBio Highlights Promising New Preclinical Obesity Antibody Data
Positive
Jul 1, 2026
On July 1, 2026, iBio reported new preclinical data from an obese non-human primate study of IBIO-610, a potential first-in-class Activin E antibody for obesity and related disorders. A single dose reduced active Activin E in all treated animals b...
Business Operations and StrategyExecutive/Board Changes
iBio Strengthens Board with Appointment of Dr. Stoner
Positive
May 8, 2026
On May 7, 2026, iBio’s board appointed veteran biotech executive Dr. Elizabeth Stoner as a Class II director and member of the Compensation Committee, filling the vacancy created by the same-day resignation of director Evert Schimmelpennink,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.